Protein Derivatives and Yeast Extract Group

Information sheet

Protein Derivatives and Yeast Extract Group

These substances were identified for action under the Chemicals Management Plan (CMP). The screening assessment focuses on 4 substances referred to collectively as the Protein Derivatives and Yeast Extract Group.

Summary of publications
Timelines

Summary of publications
Substance group	CAS RN	Common name	DSL name	Draft screening assessment	Proposed conclusion on section 64 criteria	Follow-up activities
Protein Derivatives and Yeast Extract Group	8013-01-2^{Table 1 footnote a}	Yeast extract	Yeast, ext.	HTML	Does not meet	None planned at this time
	9015-54-7^{Table 1 footnote a},^{Table 1 footnote b}	n/a	Protein hydrolyzates
	92113-31-0^{Table 1 footnote a},^{Table 1 footnote b}	Collagen hydrolyzates	Collagens, hydrolyzates
	111174-63-1^{Table 1 footnote a}	Isostearoyl hydrolyzed collagen	Protein hydrolyzates, leather, reaction products with isostearoyl chloride
Table 1 footnote a This CAS RN is a UVCB (unknown or variable composition, complex reaction products, or biological materials). Return to first Table 1 footnote a referrer Table 1 footnote b This substance was not identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999 but was included in this assessment as it was considered a priority on the basis of other human health concerns. Return to first Table 1 footnote b referrer

Timelines
Date	Activity
February 2022	Anticipated publication of the final screening assessment.
February 6, 2021	Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 155, No. 6.